Publications
Detailed Information
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, D. -W. | - |
dc.contributor.author | Kim, S. -Y. | - |
dc.contributor.author | Kim, H. -K. | - |
dc.contributor.author | Kim, S. -W. | - |
dc.contributor.author | Shin, S. W. | - |
dc.contributor.author | Kim, J. S. | - |
dc.contributor.author | Park, K. | - |
dc.contributor.author | Lee, M. Y. | - |
dc.contributor.author | Heo, D. S. | - |
dc.date.accessioned | 2010-01-07T02:02:52Z | - |
dc.date.available | 2010-01-07T02:02:52Z | - |
dc.date.created | 2020-04-08 | - |
dc.date.issued | 2007-12 | - |
dc.identifier.citation | Annals of Oncology, Vol.18 No.12, pp.2009-2014 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 95278 | - |
dc.identifier.uri | https://hdl.handle.net/10371/27818 | - |
dc.description.abstract | Background: Genexol-PM is a novel Cremophor EL (CrEL)-free polymeric micelle formulation of paclitaxel (Taxol). This multicenter phase II study was designed to evaluate the efficacy and safety of the combination of Genexol-PM and cisplatin for the treatment of advanced non-small-cell lung cancer (NSCLC). Patients and methods: Patients with advanced NSCLC received Genexol-PM 230 mg/m(2) and cisplatin 60 mg/m(2) on day 1 of a 3-week cycle as first-line therapy. Intrapatient dose escalation of Genexol-PM to 300 mg/m(2) was carried out from the second cycle if the prespecified toxic effects were not observed after the first cycle. Results: Sixty-nine patients were enrolled in this study. Overall response rate was 37.7%. The median time to progression was 5.8 months and the median survival period was 21.7 months. The major non-hematologic toxic effects included grade 3 peripheral sensory neuropathy (13.0%) and grade 3/4 arthralgia (7.3%). Four patients (5.8%) experienced grade 3/4 hypersensitivity reactions. The major hematological toxic effects were grade 3/4 neutropenia (29.0% and 17.4%, respectively). Conclusion: Genexol-PM plus cisplatin combination chemotherapy showed significant antitumor activity. The use of CrEL-free, polymeric micelle formulation of paclitaxel allowed administration of higher doses of paclitaxel compared with the CrEL-based formulation without significant increased toxicity. | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | Oxford University Press | - |
dc.title | Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.identifier.doi | 10.1093/annonc/mdm374 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000252775800017 | - |
dc.identifier.scopusid | 2-s2.0-37349080672 | - |
dc.citation.endpage | 2014 | - |
dc.citation.number | 12 | - |
dc.citation.startpage | 2009 | - |
dc.citation.volume | 18 | - |
dc.identifier.sci | 000252775800017 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, D. -W. | - |
dc.contributor.affiliatedAuthor | Heo, D. S. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | EL | - |
dc.subject.keywordPlus | REGIMENS | - |
dc.subject.keywordPlus | TAXOL | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | Genexol-PM | - |
dc.subject.keywordAuthor | non-small-cell lung cancer | - |
dc.subject.keywordAuthor | phase II | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.